nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Clobetasol propionate—psoriasis	0.153	0.385	CbGbCtD
Duloxetine—CYP1A2—Methoxsalen—psoriasis	0.0806	0.202	CbGbCtD
Duloxetine—CYP2D6—Hydroxyurea—psoriasis	0.0726	0.182	CbGbCtD
Duloxetine—CYP2D6—Cholecalciferol—psoriasis	0.044	0.11	CbGbCtD
Duloxetine—CYP2D6—Cyclosporine—psoriasis	0.0289	0.0725	CbGbCtD
Duloxetine—CYP2D6—Dexamethasone—psoriasis	0.019	0.0478	CbGbCtD
Duloxetine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000697	0.0595	CbGpPWpGaD
Duloxetine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00065	0.0555	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—HCAR2—psoriasis	0.000476	0.0406	CbGpPWpGaD
Duloxetine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000432	0.0369	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000378	0.0323	CbGpPWpGaD
Duloxetine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000366	0.0312	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and STAT3 Signaling—STAT3—psoriasis	0.000329	0.0281	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CCL20—psoriasis	0.000293	0.025	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—HCAR2—psoriasis	0.000288	0.0246	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—CCL20—psoriasis	0.000247	0.0211	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000196	0.0168	CbGpPWpGaD
Duloxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000179	0.0153	CbGpPWpGaD
Duloxetine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000177	0.0151	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HCAR2—psoriasis	0.000163	0.0139	CbGpPWpGaD
Duloxetine—Discomfort—Betamethasone—psoriasis	0.000154	0.000261	CcSEcCtD
Duloxetine—Dyspepsia—Hydrocortisone—psoriasis	0.000154	0.000261	CcSEcCtD
Duloxetine—Haemoglobin—Methotrexate—psoriasis	0.000154	0.000261	CcSEcCtD
Duloxetine—Rash—Mycophenolic acid—psoriasis	0.000153	0.00026	CcSEcCtD
Duloxetine—Dermatitis—Mycophenolic acid—psoriasis	0.000153	0.00026	CcSEcCtD
Duloxetine—Pain—Prednisolone—psoriasis	0.000153	0.00026	CcSEcCtD
Duloxetine—Hepatitis—Methotrexate—psoriasis	0.000153	0.000259	CcSEcCtD
Duloxetine—Haemorrhage—Methotrexate—psoriasis	0.000153	0.000259	CcSEcCtD
Duloxetine—Urticaria—Mycophenolate mofetil—psoriasis	0.000152	0.000258	CcSEcCtD
Duloxetine—Headache—Mycophenolic acid—psoriasis	0.000152	0.000258	CcSEcCtD
Duloxetine—Decreased appetite—Hydrocortisone—psoriasis	0.000152	0.000258	CcSEcCtD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000152	0.013	CbGpPWpGaD
Duloxetine—Pharyngitis—Methotrexate—psoriasis	0.000152	0.000257	CcSEcCtD
Duloxetine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000152	0.000257	CcSEcCtD
Duloxetine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000152	0.000257	CcSEcCtD
Duloxetine—Urinary tract disorder—Methotrexate—psoriasis	0.000151	0.000256	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000151	0.000256	CcSEcCtD
Duloxetine—Fatigue—Hydrocortisone—psoriasis	0.000151	0.000256	CcSEcCtD
Duloxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000151	0.0129	CbGpPWpGaD
Duloxetine—Vision blurred—Prednisone—psoriasis	0.00015	0.000255	CcSEcCtD
Duloxetine—Urethral disorder—Methotrexate—psoriasis	0.00015	0.000254	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.00015	0.000254	CcSEcCtD
Duloxetine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00015	0.0128	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CCL20—psoriasis	0.00015	0.0128	CbGpPWpGaD
Duloxetine—Pain—Hydrocortisone—psoriasis	0.000149	0.000253	CcSEcCtD
Duloxetine—Oedema—Dexamethasone—psoriasis	0.000149	0.000253	CcSEcCtD
Duloxetine—Anaphylactic shock—Betamethasone—psoriasis	0.000149	0.000253	CcSEcCtD
Duloxetine—Oedema—Betamethasone—psoriasis	0.000149	0.000253	CcSEcCtD
Duloxetine—Anaphylactic shock—Dexamethasone—psoriasis	0.000149	0.000253	CcSEcCtD
Duloxetine—Insomnia—Triamcinolone—psoriasis	0.000149	0.000252	CcSEcCtD
Duloxetine—Infection—Betamethasone—psoriasis	0.000148	0.000252	CcSEcCtD
Duloxetine—Infection—Dexamethasone—psoriasis	0.000148	0.000252	CcSEcCtD
Duloxetine—Ill-defined disorder—Prednisone—psoriasis	0.000148	0.000251	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—HCAR2—psoriasis	0.000148	0.0126	CbGpPWpGaD
Duloxetine—Paraesthesia—Triamcinolone—psoriasis	0.000148	0.000251	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisolone—psoriasis	0.000147	0.00025	CcSEcCtD
Duloxetine—Visual impairment—Methotrexate—psoriasis	0.000147	0.00025	CcSEcCtD
Duloxetine—Anaemia—Prednisone—psoriasis	0.000147	0.00025	CcSEcCtD
Duloxetine—Shock—Dexamethasone—psoriasis	0.000147	0.000249	CcSEcCtD
Duloxetine—Shock—Betamethasone—psoriasis	0.000147	0.000249	CcSEcCtD
Duloxetine—Nervous system disorder—Betamethasone—psoriasis	0.000146	0.000248	CcSEcCtD
Duloxetine—Nervous system disorder—Dexamethasone—psoriasis	0.000146	0.000248	CcSEcCtD
Duloxetine—Agitation—Prednisone—psoriasis	0.000146	0.000248	CcSEcCtD
Duloxetine—Thrombocytopenia—Betamethasone—psoriasis	0.000146	0.000248	CcSEcCtD
Duloxetine—Thrombocytopenia—Dexamethasone—psoriasis	0.000146	0.000248	CcSEcCtD
Duloxetine—Tachycardia—Betamethasone—psoriasis	0.000146	0.000247	CcSEcCtD
Duloxetine—Tachycardia—Dexamethasone—psoriasis	0.000146	0.000247	CcSEcCtD
Duloxetine—Angioedema—Prednisone—psoriasis	0.000146	0.000247	CcSEcCtD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000145	0.0124	CbGpPWpGaD
Duloxetine—Hypersensitivity—Cyclosporine—psoriasis	0.000145	0.000246	CcSEcCtD
Duloxetine—Dyspepsia—Triamcinolone—psoriasis	0.000145	0.000246	CcSEcCtD
Duloxetine—Erythema multiforme—Methotrexate—psoriasis	0.000145	0.000245	CcSEcCtD
Duloxetine—Nausea—Mycophenolic acid—psoriasis	0.000144	0.000245	CcSEcCtD
Duloxetine—Hyperhidrosis—Dexamethasone—psoriasis	0.000144	0.000245	CcSEcCtD
Duloxetine—Hyperhidrosis—Betamethasone—psoriasis	0.000144	0.000245	CcSEcCtD
Duloxetine—Feeling abnormal—Hydrocortisone—psoriasis	0.000144	0.000244	CcSEcCtD
Duloxetine—Malaise—Prednisone—psoriasis	0.000144	0.000244	CcSEcCtD
Duloxetine—Vertigo—Prednisone—psoriasis	0.000143	0.000243	CcSEcCtD
Duloxetine—Eye disorder—Methotrexate—psoriasis	0.000143	0.000242	CcSEcCtD
Duloxetine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000143	0.000242	CcSEcCtD
Duloxetine—Syncope—Prednisone—psoriasis	0.000143	0.000242	CcSEcCtD
Duloxetine—Tinnitus—Methotrexate—psoriasis	0.000143	0.000242	CcSEcCtD
Duloxetine—Anorexia—Betamethasone—psoriasis	0.000142	0.000241	CcSEcCtD
Duloxetine—Anorexia—Dexamethasone—psoriasis	0.000142	0.000241	CcSEcCtD
Duloxetine—Urticaria—Prednisolone—psoriasis	0.000142	0.000241	CcSEcCtD
Duloxetine—Cardiac disorder—Methotrexate—psoriasis	0.000142	0.000241	CcSEcCtD
Duloxetine—Fatigue—Triamcinolone—psoriasis	0.000142	0.000241	CcSEcCtD
Duloxetine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000141	0.00024	CcSEcCtD
Duloxetine—Asthenia—Cyclosporine—psoriasis	0.000141	0.000239	CcSEcCtD
Duloxetine—Pain—Triamcinolone—psoriasis	0.000141	0.000239	CcSEcCtD
Duloxetine—Loss of consciousness—Prednisone—psoriasis	0.00014	0.000237	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00014	0.0119	CbGpPWpGaD
Duloxetine—Pruritus—Cyclosporine—psoriasis	0.000139	0.000236	CcSEcCtD
Duloxetine—Urticaria—Hydrocortisone—psoriasis	0.000139	0.000235	CcSEcCtD
Duloxetine—Angiopathy—Methotrexate—psoriasis	0.000139	0.000235	CcSEcCtD
Duloxetine—Immune system disorder—Methotrexate—psoriasis	0.000138	0.000234	CcSEcCtD
Duloxetine—Abdominal pain—Hydrocortisone—psoriasis	0.000138	0.000234	CcSEcCtD
Duloxetine—Body temperature increased—Hydrocortisone—psoriasis	0.000138	0.000234	CcSEcCtD
Duloxetine—Convulsion—Prednisone—psoriasis	0.000138	0.000234	CcSEcCtD
Duloxetine—Mediastinal disorder—Methotrexate—psoriasis	0.000138	0.000234	CcSEcCtD
Duloxetine—Asthenia—Mycophenolate mofetil—psoriasis	0.000138	0.000233	CcSEcCtD
Duloxetine—Hypertension—Prednisone—psoriasis	0.000138	0.000233	CcSEcCtD
Duloxetine—Chills—Methotrexate—psoriasis	0.000137	0.000233	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000136	0.000231	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000136	0.000231	CcSEcCtD
Duloxetine—Pruritus—Mycophenolate mofetil—psoriasis	0.000136	0.00023	CcSEcCtD
Duloxetine—Myalgia—Prednisone—psoriasis	0.000136	0.00023	CcSEcCtD
Duloxetine—Arthralgia—Prednisone—psoriasis	0.000136	0.00023	CcSEcCtD
Duloxetine—Feeling abnormal—Triamcinolone—psoriasis	0.000136	0.00023	CcSEcCtD
Duloxetine—Anxiety—Prednisone—psoriasis	0.000135	0.000229	CcSEcCtD
Duloxetine—Alopecia—Methotrexate—psoriasis	0.000135	0.000229	CcSEcCtD
Duloxetine—Insomnia—Betamethasone—psoriasis	0.000135	0.000229	CcSEcCtD
Duloxetine—Insomnia—Dexamethasone—psoriasis	0.000135	0.000229	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000135	0.000228	CcSEcCtD
Duloxetine—Diarrhoea—Cyclosporine—psoriasis	0.000135	0.000228	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000134	0.0115	CbGpPWpGaD
Duloxetine—Paraesthesia—Betamethasone—psoriasis	0.000134	0.000227	CcSEcCtD
Duloxetine—Paraesthesia—Dexamethasone—psoriasis	0.000134	0.000227	CcSEcCtD
Duloxetine—Discomfort—Prednisone—psoriasis	0.000134	0.000227	CcSEcCtD
Duloxetine—Mental disorder—Methotrexate—psoriasis	0.000134	0.000227	CcSEcCtD
Duloxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000133	0.0114	CbGpPWpGaD
Duloxetine—Erythema—Methotrexate—psoriasis	0.000133	0.000226	CcSEcCtD
Duloxetine—Malnutrition—Methotrexate—psoriasis	0.000133	0.000226	CcSEcCtD
Duloxetine—Hypersensitivity—Prednisolone—psoriasis	0.000132	0.000224	CcSEcCtD
Duloxetine—Dyspepsia—Betamethasone—psoriasis	0.000131	0.000223	CcSEcCtD
Duloxetine—Dyspepsia—Dexamethasone—psoriasis	0.000131	0.000223	CcSEcCtD
Duloxetine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000131	0.000223	CcSEcCtD
Duloxetine—Urticaria—Triamcinolone—psoriasis	0.000131	0.000222	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—psoriasis	0.00013	0.000221	CcSEcCtD
Duloxetine—Body temperature increased—Triamcinolone—psoriasis	0.00013	0.000221	CcSEcCtD
Duloxetine—Dizziness—Cyclosporine—psoriasis	0.00013	0.000221	CcSEcCtD
Duloxetine—Oedema—Prednisone—psoriasis	0.00013	0.000221	CcSEcCtD
Duloxetine—Anaphylactic shock—Prednisone—psoriasis	0.00013	0.000221	CcSEcCtD
Duloxetine—Decreased appetite—Betamethasone—psoriasis	0.00013	0.00022	CcSEcCtD
Duloxetine—Decreased appetite—Dexamethasone—psoriasis	0.00013	0.00022	CcSEcCtD
Duloxetine—Infection—Prednisone—psoriasis	0.000129	0.000219	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000129	0.000219	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000129	0.000219	CcSEcCtD
Duloxetine—Back pain—Methotrexate—psoriasis	0.000129	0.000218	CcSEcCtD
Duloxetine—Hypersensitivity—Hydrocortisone—psoriasis	0.000129	0.000218	CcSEcCtD
Duloxetine—Fatigue—Dexamethasone—psoriasis	0.000129	0.000218	CcSEcCtD
Duloxetine—Fatigue—Betamethasone—psoriasis	0.000129	0.000218	CcSEcCtD
Duloxetine—Shock—Prednisone—psoriasis	0.000128	0.000217	CcSEcCtD
Duloxetine—Pain—Betamethasone—psoriasis	0.000128	0.000217	CcSEcCtD
Duloxetine—Pain—Dexamethasone—psoriasis	0.000128	0.000217	CcSEcCtD
Duloxetine—Nervous system disorder—Prednisone—psoriasis	0.000128	0.000216	CcSEcCtD
Duloxetine—Tachycardia—Prednisone—psoriasis	0.000127	0.000215	CcSEcCtD
Duloxetine—Dizziness—Mycophenolate mofetil—psoriasis	0.000127	0.000215	CcSEcCtD
Duloxetine—Skin disorder—Prednisone—psoriasis	0.000126	0.000214	CcSEcCtD
Duloxetine—Hyperhidrosis—Prednisone—psoriasis	0.000126	0.000213	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—psoriasis	0.000126	0.000213	CcSEcCtD
Duloxetine—Asthenia—Hydrocortisone—psoriasis	0.000125	0.000213	CcSEcCtD
Duloxetine—Vomiting—Cyclosporine—psoriasis	0.000125	0.000212	CcSEcCtD
Duloxetine—Rash—Cyclosporine—psoriasis	0.000124	0.00021	CcSEcCtD
Duloxetine—Anorexia—Prednisone—psoriasis	0.000124	0.00021	CcSEcCtD
Duloxetine—Dermatitis—Cyclosporine—psoriasis	0.000124	0.00021	CcSEcCtD
Duloxetine—Pruritus—Hydrocortisone—psoriasis	0.000124	0.00021	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—psoriasis	0.000124	0.00021	CcSEcCtD
Duloxetine—Headache—Cyclosporine—psoriasis	0.000123	0.000209	CcSEcCtD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000123	0.0105	CbGpPWpGaD
Duloxetine—Anaemia—Methotrexate—psoriasis	0.000123	0.000209	CcSEcCtD
Duloxetine—Feeling abnormal—Betamethasone—psoriasis	0.000123	0.000209	CcSEcCtD
Duloxetine—Feeling abnormal—Dexamethasone—psoriasis	0.000123	0.000209	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000122	0.000207	CcSEcCtD
Duloxetine—Gastrointestinal pain—Betamethasone—psoriasis	0.000122	0.000207	CcSEcCtD
Duloxetine—Vomiting—Mycophenolate mofetil—psoriasis	0.000122	0.000207	CcSEcCtD
Duloxetine—Hypersensitivity—Triamcinolone—psoriasis	0.000121	0.000206	CcSEcCtD
Duloxetine—Rash—Mycophenolate mofetil—psoriasis	0.000121	0.000205	CcSEcCtD
Duloxetine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000121	0.000205	CcSEcCtD
Duloxetine—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.00012	0.0103	CbGpPWpGaD
Duloxetine—Headache—Mycophenolate mofetil—psoriasis	0.00012	0.000204	CcSEcCtD
Duloxetine—Malaise—Methotrexate—psoriasis	0.00012	0.000204	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—psoriasis	0.00012	0.000203	CcSEcCtD
Duloxetine—Diarrhoea—Hydrocortisone—psoriasis	0.00012	0.000203	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—psoriasis	0.000119	0.000202	CcSEcCtD
Duloxetine—Urticaria—Betamethasone—psoriasis	0.000119	0.000201	CcSEcCtD
Duloxetine—Urticaria—Dexamethasone—psoriasis	0.000119	0.000201	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Prednisone—psoriasis	0.000118	0.000201	CcSEcCtD
Duloxetine—Dizziness—Prednisolone—psoriasis	0.000118	0.000201	CcSEcCtD
Duloxetine—Asthenia—Triamcinolone—psoriasis	0.000118	0.0002	CcSEcCtD
Duloxetine—Body temperature increased—Betamethasone—psoriasis	0.000118	0.0002	CcSEcCtD
Duloxetine—Abdominal pain—Betamethasone—psoriasis	0.000118	0.0002	CcSEcCtD
Duloxetine—Abdominal pain—Dexamethasone—psoriasis	0.000118	0.0002	CcSEcCtD
Duloxetine—Body temperature increased—Dexamethasone—psoriasis	0.000118	0.0002	CcSEcCtD
Duloxetine—Insomnia—Prednisone—psoriasis	0.000118	0.000199	CcSEcCtD
Duloxetine—Nausea—Cyclosporine—psoriasis	0.000117	0.000198	CcSEcCtD
Duloxetine—Paraesthesia—Prednisone—psoriasis	0.000117	0.000198	CcSEcCtD
Duloxetine—Pruritus—Triamcinolone—psoriasis	0.000116	0.000197	CcSEcCtD
Duloxetine—Cough—Methotrexate—psoriasis	0.000116	0.000197	CcSEcCtD
Duloxetine—Dizziness—Hydrocortisone—psoriasis	0.000116	0.000196	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—psoriasis	0.000115	0.000196	CcSEcCtD
Duloxetine—Dyspepsia—Prednisone—psoriasis	0.000114	0.000194	CcSEcCtD
Duloxetine—Nausea—Mycophenolate mofetil—psoriasis	0.000114	0.000193	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—psoriasis	0.000113	0.000192	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—psoriasis	0.000113	0.000192	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—psoriasis	0.000113	0.000192	CcSEcCtD
Duloxetine—Decreased appetite—Prednisone—psoriasis	0.000113	0.000192	CcSEcCtD
Duloxetine—Rash—Prednisolone—psoriasis	0.000113	0.000191	CcSEcCtD
Duloxetine—Dermatitis—Prednisolone—psoriasis	0.000113	0.000191	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000113	0.000191	CcSEcCtD
Duloxetine—Fatigue—Prednisone—psoriasis	0.000112	0.00019	CcSEcCtD
Duloxetine—Headache—Prednisolone—psoriasis	0.000112	0.00019	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—psoriasis	0.000112	0.00019	CcSEcCtD
Duloxetine—Constipation—Prednisone—psoriasis	0.000111	0.000189	CcSEcCtD
Duloxetine—Vomiting—Hydrocortisone—psoriasis	0.000111	0.000188	CcSEcCtD
Duloxetine—Rash—Hydrocortisone—psoriasis	0.00011	0.000187	CcSEcCtD
Duloxetine—Dermatitis—Hydrocortisone—psoriasis	0.00011	0.000187	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—psoriasis	0.00011	0.000186	CcSEcCtD
Duloxetine—Headache—Hydrocortisone—psoriasis	0.000109	0.000186	CcSEcCtD
Duloxetine—Dizziness—Triamcinolone—psoriasis	0.000109	0.000185	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—psoriasis	0.000109	0.000184	CcSEcCtD
Duloxetine—Infection—Methotrexate—psoriasis	0.000108	0.000183	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisone—psoriasis	0.000107	0.000182	CcSEcCtD
Duloxetine—Asthenia—Betamethasone—psoriasis	0.000107	0.000182	CcSEcCtD
Duloxetine—Asthenia—Dexamethasone—psoriasis	0.000107	0.000182	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—psoriasis	0.000107	0.000181	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—psoriasis	0.000106	0.00018	CcSEcCtD
Duloxetine—Gastrointestinal pain—Prednisone—psoriasis	0.000106	0.00018	CcSEcCtD
Duloxetine—Nausea—Prednisolone—psoriasis	0.000106	0.00018	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—HCAR2—psoriasis	0.000106	0.00907	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000106	0.00906	CbGpPWpGaD
Duloxetine—Pruritus—Betamethasone—psoriasis	0.000106	0.000179	CcSEcCtD
Duloxetine—Pruritus—Dexamethasone—psoriasis	0.000106	0.000179	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—psoriasis	0.000106	0.000179	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—psoriasis	0.000105	0.000178	CcSEcCtD
Duloxetine—Vomiting—Triamcinolone—psoriasis	0.000105	0.000177	CcSEcCtD
Duloxetine—Nausea—Hydrocortisone—psoriasis	0.000104	0.000176	CcSEcCtD
Duloxetine—Rash—Triamcinolone—psoriasis	0.000104	0.000176	CcSEcCtD
Duloxetine—Dermatitis—Triamcinolone—psoriasis	0.000104	0.000176	CcSEcCtD
Duloxetine—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.000104	0.00885	CbGpPWpGaD
Duloxetine—Anorexia—Methotrexate—psoriasis	0.000104	0.000176	CcSEcCtD
Duloxetine—Urticaria—Prednisone—psoriasis	0.000103	0.000175	CcSEcCtD
Duloxetine—Headache—Triamcinolone—psoriasis	0.000103	0.000175	CcSEcCtD
Duloxetine—Abdominal pain—Prednisone—psoriasis	0.000103	0.000174	CcSEcCtD
Duloxetine—Body temperature increased—Prednisone—psoriasis	0.000103	0.000174	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000103	0.00877	CbGpPWpGaD
Duloxetine—Diarrhoea—Dexamethasone—psoriasis	0.000102	0.000173	CcSEcCtD
Duloxetine—Diarrhoea—Betamethasone—psoriasis	0.000102	0.000173	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—psoriasis	9.9e-05	0.000168	CcSEcCtD
Duloxetine—Dizziness—Dexamethasone—psoriasis	9.88e-05	0.000167	CcSEcCtD
Duloxetine—Dizziness—Betamethasone—psoriasis	9.88e-05	0.000167	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—psoriasis	9.83e-05	0.000167	CcSEcCtD
Duloxetine—Nausea—Triamcinolone—psoriasis	9.78e-05	0.000166	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—psoriasis	9.76e-05	0.000165	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—psoriasis	9.66e-05	0.000164	CcSEcCtD
Duloxetine—Hypersensitivity—Prednisone—psoriasis	9.58e-05	0.000162	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—psoriasis	9.57e-05	0.000162	CcSEcCtD
Duloxetine—Vomiting—Dexamethasone—psoriasis	9.49e-05	0.000161	CcSEcCtD
Duloxetine—Vomiting—Betamethasone—psoriasis	9.49e-05	0.000161	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—psoriasis	9.45e-05	0.00016	CcSEcCtD
Duloxetine—Rash—Dexamethasone—psoriasis	9.42e-05	0.00016	CcSEcCtD
Duloxetine—Rash—Betamethasone—psoriasis	9.42e-05	0.00016	CcSEcCtD
Duloxetine—Dermatitis—Dexamethasone—psoriasis	9.41e-05	0.00016	CcSEcCtD
Duloxetine—Dermatitis—Betamethasone—psoriasis	9.41e-05	0.00016	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—psoriasis	9.38e-05	0.000159	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—psoriasis	9.37e-05	0.000159	CcSEcCtD
Duloxetine—Headache—Betamethasone—psoriasis	9.36e-05	0.000159	CcSEcCtD
Duloxetine—Headache—Dexamethasone—psoriasis	9.36e-05	0.000159	CcSEcCtD
Duloxetine—Asthenia—Prednisone—psoriasis	9.33e-05	0.000158	CcSEcCtD
Duloxetine—Pain—Methotrexate—psoriasis	9.29e-05	0.000158	CcSEcCtD
Duloxetine—Pruritus—Prednisone—psoriasis	9.2e-05	0.000156	CcSEcCtD
Duloxetine—SLC6A3—NRF2 pathway—TGFA—psoriasis	9.18e-05	0.00784	CbGpPWpGaD
Duloxetine—SLC6A4—Monoamine Transport—TNF—psoriasis	8.97e-05	0.00766	CbGpPWpGaD
Duloxetine—Feeling abnormal—Methotrexate—psoriasis	8.96e-05	0.000152	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	8.92e-05	0.00762	CbGpPWpGaD
Duloxetine—Diarrhoea—Prednisone—psoriasis	8.9e-05	0.000151	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—psoriasis	8.89e-05	0.000151	CcSEcCtD
Duloxetine—Nausea—Dexamethasone—psoriasis	8.87e-05	0.00015	CcSEcCtD
Duloxetine—Nausea—Betamethasone—psoriasis	8.87e-05	0.00015	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—HCAR2—psoriasis	8.73e-05	0.00746	CbGpPWpGaD
Duloxetine—Urticaria—Methotrexate—psoriasis	8.63e-05	0.000146	CcSEcCtD
Duloxetine—Dizziness—Prednisone—psoriasis	8.6e-05	0.000146	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—psoriasis	8.59e-05	0.000146	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—psoriasis	8.59e-05	0.000146	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—CCL20—psoriasis	8.45e-05	0.00722	CbGpPWpGaD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—STAT3—psoriasis	8.31e-05	0.0071	CbGpPWpGaD
Duloxetine—Vomiting—Prednisone—psoriasis	8.27e-05	0.00014	CcSEcCtD
Duloxetine—Rash—Prednisone—psoriasis	8.2e-05	0.000139	CcSEcCtD
Duloxetine—Dermatitis—Prednisone—psoriasis	8.19e-05	0.000139	CcSEcCtD
Duloxetine—Headache—Prednisone—psoriasis	8.15e-05	0.000138	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—RUNX3—psoriasis	8.09e-05	0.00691	CbGpPWpGaD
Duloxetine—Hypersensitivity—Methotrexate—psoriasis	8.01e-05	0.000136	CcSEcCtD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CXCL8—psoriasis	7.91e-05	0.00675	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HCAR2—psoriasis	7.82e-05	0.00668	CbGpPWpGaD
Duloxetine—Asthenia—Methotrexate—psoriasis	7.8e-05	0.000132	CcSEcCtD
Duloxetine—Nausea—Prednisone—psoriasis	7.72e-05	0.000131	CcSEcCtD
Duloxetine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	7.72e-05	0.00659	CbGpPWpGaD
Duloxetine—SLC6A2—Monoamine Transport—TNF—psoriasis	7.71e-05	0.00659	CbGpPWpGaD
Duloxetine—Pruritus—Methotrexate—psoriasis	7.69e-05	0.00013	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—CCL20—psoriasis	7.68e-05	0.00656	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	7.62e-05	0.0065	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TAGAP—psoriasis	7.57e-05	0.00646	CbGpPWpGaD
Duloxetine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	7.49e-05	0.00639	CbGpPWpGaD
Duloxetine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	7.45e-05	0.00636	CbGpPWpGaD
Duloxetine—Diarrhoea—Methotrexate—psoriasis	7.44e-05	0.000126	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	7.29e-05	0.00623	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.25e-05	0.00619	CbGpPWpGaD
Duloxetine—Dizziness—Methotrexate—psoriasis	7.19e-05	0.000122	CcSEcCtD
Duloxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.98e-05	0.00596	CbGpPWpGaD
Duloxetine—Vomiting—Methotrexate—psoriasis	6.91e-05	0.000117	CcSEcCtD
Duloxetine—Rash—Methotrexate—psoriasis	6.85e-05	0.000116	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—psoriasis	6.85e-05	0.000116	CcSEcCtD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	6.85e-05	0.00585	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—TNF—psoriasis	6.83e-05	0.00584	CbGpPWpGaD
Duloxetine—Headache—Methotrexate—psoriasis	6.81e-05	0.000115	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—HCAR2—psoriasis	6.79e-05	0.0058	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—CXCL8—psoriasis	6.67e-05	0.0057	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	6.64e-05	0.00567	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	6.54e-05	0.00559	CbGpPWpGaD
Duloxetine—Nausea—Methotrexate—psoriasis	6.46e-05	0.000109	CcSEcCtD
Duloxetine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	6.45e-05	0.00551	CbGpPWpGaD
Duloxetine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	6.44e-05	0.0055	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL13—psoriasis	6.39e-05	0.00545	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	6.34e-05	0.00542	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—CP—psoriasis	6.06e-05	0.00518	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HCAR2—psoriasis	6e-05	0.00513	CbGpPWpGaD
Duloxetine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	5.64e-05	0.00482	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CCL20—psoriasis	5.52e-05	0.00471	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HCAR2—psoriasis	5.45e-05	0.00466	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.34e-05	0.00456	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.3e-05	0.00453	CbGpPWpGaD
Duloxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.86e-05	0.00415	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	4.63e-05	0.00396	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCL20—psoriasis	4.54e-05	0.00387	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	4.46e-05	0.00381	CbGpPWpGaD
Duloxetine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	4.45e-05	0.0038	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	4.42e-05	0.00378	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	4.16e-05	0.00355	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL20—psoriasis	4.06e-05	0.00347	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CXCL8—psoriasis	4.04e-05	0.00345	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HCAR2—psoriasis	4.02e-05	0.00343	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL10—psoriasis	4e-05	0.00341	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	3.88e-05	0.00332	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HCAR2—psoriasis	3.84e-05	0.00328	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	3.77e-05	0.00322	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	3.63e-05	0.0031	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL20—psoriasis	3.53e-05	0.00301	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HCAR2—psoriasis	3.49e-05	0.00298	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	3.48e-05	0.00297	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	3.37e-05	0.00288	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	3.32e-05	0.00283	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.25e-05	0.00277	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HCAR2—psoriasis	3.22e-05	0.00275	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.13e-05	0.00268	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCL20—psoriasis	3.12e-05	0.00266	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	3.08e-05	0.00263	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.95e-05	0.00252	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	2.94e-05	0.00251	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL20—psoriasis	2.83e-05	0.00242	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TAGAP—psoriasis	2.79e-05	0.00238	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	2.75e-05	0.00235	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.71e-05	0.00231	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.61e-05	0.00223	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	2.53e-05	0.00216	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SOCS1—psoriasis	2.5e-05	0.00213	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TYK2—psoriasis	2.38e-05	0.00203	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HCAR2—psoriasis	2.37e-05	0.00203	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.37e-05	0.00202	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCL20—psoriasis	2.3e-05	0.00196	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL8—psoriasis	2.28e-05	0.00195	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.24e-05	0.00191	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.18e-05	0.00187	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL20—psoriasis	2.09e-05	0.00178	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL8—psoriasis	2.07e-05	0.00177	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HCAR2—psoriasis	2.06e-05	0.00176	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TAGAP—psoriasis	2.06e-05	0.00176	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	2.04e-05	0.00174	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—JUN—psoriasis	2.03e-05	0.00173	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.03e-05	0.00173	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.03e-05	0.00173	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCL20—psoriasis	1.99e-05	0.0017	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.96e-05	0.00167	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—psoriasis	1.95e-05	0.00167	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	1.94e-05	0.00166	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—APOE—psoriasis	1.84e-05	0.00157	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—LEP—psoriasis	1.84e-05	0.00157	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	1.82e-05	0.00155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL20—psoriasis	1.81e-05	0.00155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TAGAP—psoriasis	1.79e-05	0.00153	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	1.77e-05	0.00152	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NFKBIA—psoriasis	1.72e-05	0.00147	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL20—psoriasis	1.67e-05	0.00143	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	1.66e-05	0.00142	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NDUFA5—psoriasis	1.55e-05	0.00133	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	1.52e-05	0.0013	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCL8—psoriasis	1.49e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.44e-05	0.00123	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TYK2—psoriasis	1.41e-05	0.0012	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.32e-05	0.00113	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.32e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.25e-05	0.00107	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL20—psoriasis	1.23e-05	0.00105	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	1.23e-05	0.00105	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.23e-05	0.00105	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCL8—psoriasis	1.22e-05	0.00105	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—psoriasis	1.16e-05	0.000994	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—JUN—psoriasis	1.14e-05	0.000972	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.12e-05	0.000955	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL8—psoriasis	1.1e-05	0.000937	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NFKB1—psoriasis	1.1e-05	0.000936	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.09e-05	0.000934	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL20—psoriasis	1.07e-05	0.000914	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—psoriasis	9.95e-06	0.000849	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—psoriasis	9.85e-06	0.000841	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—psoriasis	9.53e-06	0.000814	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	9.49e-06	0.000811	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SOCS1—psoriasis	9.21e-06	0.000787	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TYK2—psoriasis	8.78e-06	0.00075	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—psoriasis	8.42e-06	0.000719	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—psoriasis	7.65e-06	0.000653	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—psoriasis	7.52e-06	0.000642	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—psoriasis	6.88e-06	0.000587	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—psoriasis	6.8e-06	0.000581	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—psoriasis	6.8e-06	0.000581	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SOCS1—psoriasis	6.78e-06	0.000579	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TYK2—psoriasis	6.47e-06	0.000552	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CARM1—psoriasis	6.45e-06	0.000551	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKBIA—psoriasis	6.33e-06	0.000541	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	6.2e-06	0.00053	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS1—psoriasis	5.89e-06	0.000503	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.86e-06	0.000501	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—psoriasis	5.63e-06	0.000481	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TYK2—psoriasis	5.62e-06	0.00048	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CARM1—psoriasis	5.46e-06	0.000467	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	5.39e-06	0.00046	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TYK2—psoriasis	5.19e-06	0.000443	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.11e-06	0.000436	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—psoriasis	5.01e-06	0.000428	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—psoriasis	5.01e-06	0.000428	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—psoriasis	4.89e-06	0.000418	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	4.67e-06	0.000398	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—psoriasis	4.52e-06	0.000386	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—psoriasis	4.35e-06	0.000371	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—psoriasis	4.35e-06	0.000371	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—psoriasis	4.3e-06	0.000367	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—psoriasis	4.2e-06	0.000359	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKBIA—psoriasis	4.05e-06	0.000346	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKB1—psoriasis	4.04e-06	0.000345	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAT—psoriasis	3.97e-06	0.000339	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TYK2—psoriasis	3.82e-06	0.000326	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—psoriasis	3.67e-06	0.000313	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—psoriasis	3.63e-06	0.00031	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAT—psoriasis	3.36e-06	0.000287	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—psoriasis	3.33e-06	0.000284	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TYK2—psoriasis	3.32e-06	0.000283	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—psoriasis	3.16e-06	0.00027	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—psoriasis	3.09e-06	0.000264	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—psoriasis	3.08e-06	0.000263	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKB1—psoriasis	2.98e-06	0.000254	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—psoriasis	2.89e-06	0.000247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—psoriasis	2.77e-06	0.000237	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—psoriasis	2.75e-06	0.000235	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—psoriasis	2.7e-06	0.000231	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—psoriasis	2.69e-06	0.000229	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—psoriasis	2.68e-06	0.000229	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—psoriasis	2.68e-06	0.000228	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—psoriasis	2.61e-06	0.000223	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKB1—psoriasis	2.59e-06	0.000221	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—psoriasis	2.54e-06	0.000217	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—psoriasis	2.35e-06	0.0002	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—psoriasis	2.32e-06	0.000198	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—psoriasis	2.27e-06	0.000194	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—psoriasis	2.04e-06	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—psoriasis	1.87e-06	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—psoriasis	1.77e-06	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—psoriasis	1.62e-06	0.000139	CbGpPWpGaD
